BROOKS

Brooks Laboratories Ltd.

NSE: BROOKS

BSE: 533543

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

63.30-5.2 (-7.58%)

8 Sep, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

75.6 / 100

Value Score

68.0 / 100

Price Momentum Score

10.8 / 100

QVM Score

49.0 / 100

Key Metrics

Market Cap

186.46

P/E (TTM)

7.58

P/B

1.52

P/S (TTM)

2.24

EV/EBITDA

CAPE (5Y)

ROE (TTM)

22.27

ROCE (TTM)

4.62

ROA (TTM)

18.08

Avg 3Y ROE

-6.00

Earnings 3Y CAGR

Sales 3Y CAGR

10.42

Sales 5Y CAGR

-0.77

Debt/Equity

0.07

Consensus TP

Strong Buy %

Promoter Holding

52.62

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Brooks Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Stock is cheap and PE TTM is at a discount to industry median

PE TTM of 7.58 indicates that the stock is cheap on a standalone basis. Discount to industry median P/E is decent at -76.15%

What is P/E Ratio?

Median: 31.78

Value 7.58

-0.96721.13

High and improving ROE

The company reported strong ROE of 22.27% for 12-month ended 30 Jun 2026 and ROE improved by 3445 bps from 1 year ago

What is ROE (FY)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.07 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.01 in the last 1 year

What is Debt to Equity?

Negative

Weak price momentum

Price Momentum score of 10.8 indicates that the stock has weak price momentum. Research has shown that stocks with lower momentum continue to underperform in the near term

What is Price Momentum score?

10.8 / 100

Low but stable operating margin

The company reported low operating margin of 6.38% for 12-month ended 30 Jun 2026 and operating margin improved marginally by 79 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of -23.02% for 12-month ended 30 Jun 2026 and the growth was 33.61 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value -23.02

-99.6111701.8

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 46.5 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

46.5 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Brooks Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Brooks Laboratories Ltd. Shareholding Pattern

Quarterly breakdown of Brooks Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	63.59	63.59	63.59	63.59	63.59	59.06	52.62	52.62	52.62	52.62	52.62	52.62
Indian Promoter	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	66.41	63.59	63.59	63.59	63.59	63.59	59.06	52.62	52.62	52.62	52.62	52.62	52.62
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	0.00	0.00	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	2.46	3.86	3.86	3.86	3.88	3.87	9.96	9.90	9.91	9.99	10.07	9.90
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.46	3.86	3.86	3.86	3.86	3.86	9.90	9.90	9.90	9.90	9.90	9.90
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.01	0.05	0.00	0.01	0.09	0.17	0.00
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Institution	33.58	33.58	33.59	33.59	33.59	33.59	33.59	33.59	33.59	33.59	33.59	33.58	33.59	33.59	33.94	32.55	32.55	32.55	32.53	37.08	37.43	37.48	37.48	37.39	37.32	37.48
Bodies Corporate	2.84	2.33	2.57	3.13	3.08	2.79	2.77	2.71	2.59	2.78	2.89	2.93	3.21	3.24	4.28	4.47	4.37	4.17	2.01	2.67	3.48	3.32	2.84	2.46	2.94	3.29
Others (incl. Retail) No. of shareholders	30.74 11,482	31.25 11,579	31.02 11,091	30.46 10,810	30.51 10,619	30.80 10,352	30.82 10,307	30.88 10,846	31.00 11,077	30.81 11,037	30.70 10,448	30.65 10,334	30.38 10,632	30.35 11,141	29.66 10,602	28.08 9,942	28.18 11,348	28.38 11,456	30.52 11,204	34.41 10,448	33.95 10,458	34.16 10,243	34.64 10,008	34.93 10,461	34.38 10,676	34.19 11,096

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Brooks Laboratories Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Aryan Mahajan Promoter Group	November-2024	Market Sale (Disposal) 17th Nov 2024	4.60 %	₹ 137.40	4.80 lac	₹ 6.60 cr
Atul Ranchal Promoter	November-2024	Market Sale (Disposal) 17th Nov 2024	22.36 %	₹ 137.40	2.00 lac	₹ 2.75 cr
Atul Ranchal Promoter	November-2024	Market Sale (Disposal) 17th Nov 2024	23.86 %	₹ 136.40	3.95 lac	₹ 5.39 cr
Atul Ranchal Promoter	November-2024	Market Sale (Disposal) 17th Nov 2024	23.86 %	₹ 136.40	3.95 lac	₹ 5.39 cr
Saras Gupta Promoter Group	November-2024	Market Sale (Disposal) 17th Nov 2024	3.07 %	₹ 137.40	1.15 lac	₹ 1.59 cr

Corporate Actions

History of Brooks Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Rights Issue(1 new shares @ ₹75 for 16 existing shares)
Ex-date: 28th Jul 2023Announced on: 25th Jan 2023
"Rights ISIN INE650L20011CINS Y0R84Z113SEDOL BR1YGP6."
Rights Issue(9 new shares @ ₹20 for 20 existing shares)
Ex-date: 11th Feb 2020Announced on: 31st Jan 2020

Company Profile

Overview of Brooks Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company. The Company specializes in supplying pharmaceutical products to government bodies, healthcare institutions, and large organizations. It operates through two segments, which include manufacturing and trading. The manu...

Key personnel

Mr. Prashant Rathi

Chief Executive Officer, Chief Financial Officer

Mr. Rajesh Mahajan

President - Procurement

Ms. Krutika Mohan Rane

Compliance Officer, Company Secretary

Dr. Durga Sankar MaityD

Whole-Time Director

Mr. Bhushan Singh RanaD

Whole-Time Director

Mr. Jitendra Pratap SinghD

Whole-Time Director

Mr. Lalit MahajanD

Non-Executive Independent Director

Mr. Manav MahajanD

Non-Executive Independent Director

View all

Incorporated on

23 Jan 2002

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

347

IPO date

02 Sep 2011

Free Float

1,29,96,366

Website

https://www.brookslabs.net/

Phone no.

+911795654001

Address

502, Kanakia Atrium-2,, Next to Hotel Courtyard Marriott,, Andheri Kurla Road,, MUMBAI, 400093, India

Frequently Asked Questions

What is the current share price of Brooks Laboratories Ltd.?

The current share price of Brooks Laboratories Ltd. is ₹ 63.30 as of 8 Sep 2026.

What is the market capitalisation of Brooks Laboratories Ltd.?

The market capitalisation of Brooks Laboratories Ltd. stands at ₹ 186.46 Cr.

What is the PE ratio of Brooks Laboratories Ltd.?

The Price-to-Earnings (PE) ratio of Brooks Laboratories Ltd. is 7.58 as of the latest trailing twelve months data.

What is the ROE and ROCE of Brooks Laboratories Ltd.?

Brooks Laboratories Ltd. has a Return on Equity (ROE) of 22.27% and a Return on Capital Employed (ROCE) of 4.62% as per the latest financial reports.

What is the 52-week high and low of Brooks Laboratories Ltd.?

The 52-week high of Brooks Laboratories Ltd. is - and the 52-week low is -.

What is the dividend yield of Brooks Laboratories Ltd.?

The dividend yield of Brooks Laboratories Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Brooks Laboratories Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 9.90% and retail/public investors hold 34.19% of Brooks Laboratories Ltd. shares.

What sector does Brooks Laboratories Ltd. belong to?

Brooks Laboratories Ltd. operates in the Healthcare sector.

What is the beta of Brooks Laboratories Ltd.?

The beta of Brooks Laboratories Ltd. is 1.43, indicating its price volatility relative to the broader market. Over the past 1 year, Brooks Laboratories Ltd. has delivered an absolute return of -53.37%.

What is the RSI of Brooks Laboratories Ltd.?

The 14-day Relative Strength Index (RSI) of Brooks Laboratories Ltd. is 47.92, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Brooks Laboratories Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Brooks Laboratories Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Corporate Actions